These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Cutaneous hyperpigmentation following bleomycin sclerotherapy for vascular malformations.
    Author: Davis KP, Gaffey MM, Kompelli AR, Richter GT.
    Journal: Pediatr Dermatol; 2022 Jan; 39(1):103-106. PubMed ID: 34897790.
    Abstract:
    Systemic bleomycin therapy is associated with pulmonary fibrosis and cutaneous side effects. While it is believed that there is little to no systemic distribution of bleomycin when utilized to treat vascular malformations (VMs), we present a case series in which cutaneous, adhesive-related hyperpigmentation suggests that there is systemic egress of bleomycin following direct puncture sclerotherapy (DPS). This risk of hyperpigmentation after intralesional bleomycin should be discussed with patients, and steps to minimize the chances of it occurring should be implemented.
    [Abstract] [Full Text] [Related] [New Search]